Trial intelligence / Profile preview

Open-label 7-day monotherapy trial of TMC435350 in HCV genotypes 2–6

2008-005709-20Phase 2Completed

Sponsor
Tibotec
Start
Nov 2008
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 2, open-label, single-arm trial of simeprevir in hepatitis C virus infection, sponsored by Tibotec. Primary endpoint: Antiviral activity of TMC435350 over 7 days. Started Nov 2008; status: completed.

02

Drugs

simeprevir
03

Conditions

hepatitis C virus infection

Beyond the preview

Go deeper on 2008-005709-20.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2008-005709-20.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call